Sanofi filings document a foreign private issuer’s biopharma disclosures through Form 6-K reports and exhibits furnished under the Exchange Act. The reports include quarterly operating updates for pharma launches, Dupixent, vaccines, research and development expense, business EPS and IFRS EPS, along with pipeline and regulatory disclosures involving immunology, respiratory disease, rare disease and partnered medicines.
The filing record also covers capital structure and governance events, including fixed-rate notes issued under Sanofi’s Euro Medium Term Note programme, share buyback activity, completed acquisitions and annual general meeting resolutions. These materials identify Sanofi as an R&D-driven, AI-powered biopharma company listed on Euronext and Nasdaq.
Sanofi filed a report summarizing two regulatory milestones from September 2025. The company notes a press release on a positive CHMP opinion in the European Union for Dupixent, developed with Regeneron, for treating chronic spontaneous urticaria. A second press release covers an update on the U.S. regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis. The report itself mainly serves to formally furnish these press releases to investors.
Sanofi reported three corporate press developments in September 2025 affecting its late-stage pipeline. On September 10, 2025, Tzield was approved in China as the first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes, marking a regulatory milestone for that indication in China. On September 11, 2025, Sanofi announced that SAR402663 received fast track designation in the U.S. for neovascular age-related macular degeneration, which can accelerate development and review. On September 17, 2025, Sanofi reported positive phase 2a results for brivekimig in hidradenitis suppurativa. The report is signed by Alexandra Roger, Head of Legal Corporate & Finance.